NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk CEO Confident in Diverse Obesity Drug Market, Downplays "Winner-Take-All" Scenario
Novo Nordisk's CEO, Mike Doustdar, stated that he does not foresee a "winner-take-all" market for obesity drugs. In an interview with Reuters, he compared the...
Novo Nordisk Downgraded to 'Hold' by Berenberg Amid Competitive Pressure
Berenberg Bank downgraded Novo Nordisk (NVO) from "buy" to "hold" on Wednesday. The bank also reduced its price target for Novo Nordisk's American depositary...
Novo Nordisk launches Awiqli, first once-weekly US insulin for adult diabetes
Novo Nordisk launched Awiqli in the U.S. as the first once-weekly basal insulin for adults with type 2 diabetes. The new treatment option aims to improve...
🔴 Novo Nordisk is trading 3.02% down in pre-market as no clear company-specific catalyst emerges
Novo Nordisk is trading 3.02% down at $45.75, with no fresh company-specific announcement clearly explaining the August 12 pre-market decline. - It fell from...
🟢 Novo Nordisk is trading 4.4% up today after raising FY26 guidance and beating Q2 revenue expectations
Novo Nordisk is trading 4.4% up at $46.50 in pre-market action, rebounding from recent volatility as investors react to the company raising its full-year 2026...
Novo Nordisk lifts 2026 outlook after strong second quarter with 7% adjusted sales growth at CER.
Novo Nordisk reported second quarter adjusted sales growth of 7% and adjusted operating profit growth of 11%, both at constant exchange rates (CER). Citing...
Novo Nordisk's second quarter revenue beats on GLP-1 strength, but impairments hit EPS; company lifts 2026 guidance.
Novo Nordisk reported second quarter 2026 revenue of DKK 78.5 billion ($12.26 billion), beating estimates, while diluted EPS of DKK 4.75 ($0.74) missed...
🔴 Novo Nordisk falls 4.7% as Q2 results show mixed performance and impairment charges
• Novo Nordisk is trading 4.7% down today at $44.88 following the release of its Q2 2026 financial results and updated outlook today, August 4, 2026. • While...
Novo Nordisk A/S Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect Novo Nordisk to report consensus revenue of $11.27 billion and EPS of $0.82, with the current stock price of...
🔴 Novo Nordisk is trading 9.3% down today after experimental drug Ziltivekimab failed key cardiovascular trial
Novo Nordisk is trading 9.3% down at $46.82 due to significant company-specific news impacting its pipeline and legal standing: • The company announced that...
🔴 Novo Nordisk is trading 10.5% down today on U.S. obesity-drug slowdown and pricing pressure
Novo Nordisk is trading 10.5% down at $46.19 after signaling that its U.S. obesity-drug business is decelerating faster than investors expected ahead of its Q2...
Novo Nordisk Crashes 9% Before Q2 Print — Can the Wegovy Pill Outrun a Price Squeeze That Keeps Getting Worse?
Shares tumbled to $46.83 in pre-market trading, erasing a week of gains in a single session as Novo Nordisk signaled that its U.S. obesity-drug business is...
🔴 Novo Nordisk is trading 9.3% down today after ZEUS trial fails to meet primary endpoint
• Novo Nordisk is trading at $46.83 (-9.26%) in pre-market after announcing headline results from its ZEUS cardiovascular outcomes Phase 3 trial. • The trial...
Novo Nordisk faces fraud lawsuit, allegedly hid CagriSema trial protocols
A U.S. federal judge ruled Novo Nordisk must face a shareholder class-action lawsuit alleging securities fraud. The lawsuit, filed in the District of New...
🟢 Novo Nordisk is trading 3.1% up today on sector rally and defensive rotation
Novo Nordisk is trading 3.1% up at $51.19 as shares benefit from a broader healthcare sector rally and a rotation away from technology stocks. • The stock is...
Novo Nordisk Debuts World-First Weekly Diabetes Injection in China
Novo Nordisk and Fangzhou Inc. launched the diabetes treatment Kyinsu® in China. This release marks the product's global commercial debut. Kyinsu® is the...
Novo Nordisk launches cheaper Ozempic copy, targeting South Africa's grey market
Novo Nordisk will launch Extensior in South Africa on July 27. Extensior serves as a more affordable, authorized copy of the blockbuster diabetes drug...
🟢 Novo Nordisk is trading 3% up today as it rebounds from recent GLP-1 pricing concerns
Novo Nordisk is trading 3% up at $50.55, rebounding from recent weakness tied to GLP-1 pricing and reimbursement worries. • The move comes despite a warning...
Novo Nordisk launches Awiqli in India, world’s first weekly insulin
Danish pharmaceutical company Novo Nordisk launched Awiqli in India on Thursday. Awiqli is the world’s first once-weekly basal insulin approved for clinical...
Novo and Lilly face Medicare limits, restricted to heart disease patients
Medicare is expanding coverage for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Federal law prohibits Medicare Part D from covering drugs solely for weight...